BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

1:13 PM
Jan 23, 2018
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Acute myelogenous leukemia (AML)

In vitro, cell culture and mouse studies identified a peptide-based inhibitor of the MYB-CREBBP interaction that could help treat AML. The inhibitor consisted of a retro-inverso form of a MYB fragment containing D-amino acids to...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >